The Enron Discount
Transparent number-crunching is back in vogue. Companies that pursue obfuscating accounting strategies to finesse their bottom line may suffer from a new form of ED: the Enron Discount. But so long as the investment community is clamoring for a simple answer (earnings growth) to the complex question of a company's fiscal health, companies will continue to use whatever GAAP-approved means is necessary to appease.
You may also be interested in...
Dealmaking in the device industry is occasional and incremental when compared with the level of activity in pharmaceuticals, the result of that industry's maturing into a handful of dominant players, not all of which see acquisitions as strategically critical to their long-term success. The less-than-robust public market for small device companies is both symptom and cause of the device dealmaking lull. Because the markets they target are generally too small to sustain years of significant growth, few investors are willing to invest in them as stand-alone companies. And without long-term investor support, smaller firms have few options other than to sell out to large companies and little negotiating leverage when they do so.
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.